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Abstract
Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus linked to a number of B cell cancers and lymphoproliferative
disorders. During latent infection, EBV expresses 25 viral pre-microRNAs (miRNAs) and induces the expression of specific
host miRNAs, such as miR-155 and miR-21, which potentially play a role in viral oncogenesis. To date, only a limited number
of EBV miRNA targets have been identified; thus, the role of EBV miRNAs in viral pathogenesis and/or lymphomagenesis is
not well defined. Here, we used photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-
CLIP) combined with deep sequencing and computational analysis to comprehensively examine the viral and cellular miRNA
targetome in EBV strain B95-8-infected lymphoblastoid cell lines (LCLs). We identified 7,827 miRNA-interaction sites in 3,492
cellular 39UTRs. 531 of these sites contained seed matches to viral miRNAs. 24 PAR-CLIP-identified miRNA:39UTR interactions
were confirmed by reporter assays. Our results reveal that EBV miRNAs predominantly target cellular transcripts during
latent infection, thereby manipulating the host environment. Furthermore, targets of EBV miRNAs are involved in multiple
cellular processes that are directly relevant to viral infection, including innate immunity, cell survival, and cell proliferation.
Finally, we present evidence that myc-regulated host miRNAs from the miR-17/92 cluster can regulate latent viral gene
expression. This comprehensive survey of the miRNA targetome in EBV-infected B cells represents a key step towards
defining the functions of EBV-encoded miRNAs, and potentially, identifying novel therapeutic targets for EBV-associated
malignancies.
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Introduction
Epstein-Barr virus (EBV) is a ubiquitous human c-herpesvirus
that can induce the proliferation of resting B lymphocytes in vivo.
Following primary infection, EBV establishes a lifelong latent
infection and, in the absence of effective immune surveillance, can
induce lymphoproliferative diseases. EBV is associated with
numerous B cell malignancies including Hodgkin’s lymphoma
(HL), Burkitt’s lymphoma (BL), and diffuse large B cell lymphoma
(DLBCL) as well as post-transplant lymphoproliferative disorders
(PTLD) [1]. In vitro, EBV immortalizes primary human B
lymphocytes, establishing a type III latency program characterized
by the expression of a subset of viral gene products including six
EBV nuclear antigens (EBNAs), three latent membrane proteins
(LMPs), and non-coding RNAs including EBV-encoded small
RNAs (EBERs) and viral microRNAs (miRNAs) [1–6]. The
resulting lymphoblastoid cell lines (LCLs) serve as an in vitro model
for EBV-associated lymphoproliferative diseases and share many
of the characteristics of PTLD in terms of latent viral gene
expression [1].
miRNAs are ,22 nucleotide (nt) non-coding RNAs that post-
transcriptionally regulate gene expression. miRNAs are expressed
by all metazoans as well as a number of viruses. EBV encodes 25
miRNA precursors (three BHRF1 pre-miRNAs and 22 BART
pre-miRNAs), which are located in two regions of the genome [2–
6]. Expression of the BHRF1 miRNAs is restricted to type III
latency, which is observed in LCLs and PTLD, while BART
miRNAs are variably expressed in all latency stages [3,7,8]. EBV
miRNA biogenesis follows the canonical cellular miRNA biogen-
esis pathway, initiating in the nucleus with primary miRNA stem-
loops that are cleaved by Drosha, exported into the cytoplasm, and
cleaved by Dicer into ,22 nt RNA duplexes (reviewed in [9]).
One strand of the duplex is incorporated into the RNA-induced
silencing complex (RISC), which minimally consists of a mature
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guides RISC to complementary sites predominantly in 39UTRs of
target mRNAs, resulting in translational repression and/or mRNA
degradation (reviewed in [10]). Especially important for miRNA
targeting are nucleotides (nt) 2-8, minimally nt 2-7, of the mature
miRNA, termed the ‘‘seed’’ sequence, which generally binds with
perfect Watson-Crick base pairing to target mRNAs [10,11].
In addition to expressing viral miRNAs, EBV infection induces
the expression of several cellular miRNAs, including miR-155,
miR-146a, and miR-21 [12–15]. Recent studies suggest that miR-
146a functions as a tumor suppressor since genetic ablation of
miR-146a in mice induces myeloid tumors [16]. In contrast, both
miR-155 and miR-21 are over-expressed in a number of cancers,
including B cell lymphomas, and when over-expressed in
transgenic mouse models, these miRNAs induce B cell tumors
[17–19]. Recently, miR-155 has been shown to be required for the
growth and survival of LCLs in vitro [20]. In fact, miR-155
regulated pathways are likely of importance to oncogenic
herpesvirus biology in general since the related c-herpesvirus
Kaposi’s sarcoma-associated herpesvirus (KSHV), which is linked
to a number of B cell malignancies, as well as Marek’s disease virus
(MDV), which causes T cell lymphomas in chickens, both encode
functional analogs of miR-155 [21–24].
We and others have hypothesized that viral miRNAs as well as
cellular miRNAs induced by viral infection have a direct impact
on the cellular gene expression pattern that favors the establish-
ment and/or maintenance of latent infection [9,25,26]. Identifying
the targets of viral and cellular miRNAs is a key step in elucidating
their functional roles during infection as well as their potential
contributions to viral pathogenesis and lymphomagenesis. Several
studies point to important functional roles for EBV miRNAs
during the viral life cycle, including immune evasion, cell survival
and proliferation, and control of the latent/lytic switch. miR-
BART2-5p, for example, targets the lytic viral DNA polymerase
encoded by BALF5 [4,27]. miR-BART2-5p is also reported to
downregulate expression of MICB, a natural killer (NK) cell
ligand, which contributes to immune evasion [28]. Similarly, miR-
BHRF1-3 downregulates CXCL11, an interferon-inducible che-
mokine and T cell attractant [29]. Finally, LMP1 and LMP2A,
which not only contribute to the survival, proliferation and
transformation of EBV-infected cells, but are also immunogenic,
are both reported targets of EBV BART miRNAs [30,31].
Recent studies performed with EBV miRNA deletion mutants
indicate that EBV miRNAs contribute to, but are not essential for,
LCL formation in vitro [32–34]. The EBV B95-8 laboratory strain
bears a deletion within the BART region and encodes only five of
the 22 BART miRNAs. This virus can still immortalize B cells in
vitro, and inactivation of the remaining BART miRNAs has little
effect on LCL outgrowth [34]. However, mutational inactivation
of the BHRF1 miRNAs inhibits LCL outgrowth, reduces the
ability of LCLs to progress from G1 to S phase during the cell
cycle, and affects EBV latent gene expression [32–34]. The viral
miRNA targets responsible for these phenotypes are not yet
defined. Indeed, since the identification of the first EBV miRNAs
in 2004, only ten targets of EBV miRNAs have been experimen-
tally validated [4,27–31,35–38]. To date, the largest screen of
EBV miRNA targets identified 44 candidate mRNA targets in B
cells, only two of which were further validated [35]. As cellular
miRNAs are predicted to individually target more than 100
mRNAs [39], and EBV expresses at least 25 miRNAs, these 44
candidate targets represent only ,1% of the potential viral
miRNA targetome.
Here, we report the use of photoactivatable-ribonucleoside
enhance crosslinking and immunoprecipitation (PAR-CLIP) to
interrogate the viral and cellular miRNA targetome in latently
infected EBV-B95-8 LCLs. We identified over 500 canonical, 59
seed target sites for EBV-B95-8 miRNAs and over 3,000 seed
target sites for cellular miRNAs in these cells. Binding sites for
cellular miRNAs in EBV transcripts were also detected, and we
uncovered several non-canonical target sites, providing new
insight into the dynamics of miRNA regulation. We show that
EBV-B95-8 miRNAs predominantly target cellular transcripts
during latent infection and experimentally validate a number of
mRNA targets for EBV miRNAs with roles in innate immunity,
stress response, and cell signaling.
Results
miRNAs expressed in LCLs
To identify miRNA targets in LCLs, it was important to first
define the LCL miRNA transcriptome at the sequence level.
Therefore, we profiled all small RNAs, cellular and viral,
expressed in EBV-B95-8-infected LCLs using the Illumina
sequencing platform. We used the EBV-B95-8 strain primarily
due to the availability of miRNA deletion mutants that were
generated in the B95-8 background (see below). High-throughput
sequencing of four LCLs (SDLCL, LCL35, EF3D-AGO2
expressing a FLAG-tagged Ago2, and LCL-BAC) yielded over
28 million reads, of which 89.3% aligned to the human genome
and 6.9% aligned to the EBV B95-8 genome (Table S1). Reads
were then mapped to known human and viral pre-miRNAs
present in miRBASE v16.0. We identified miRNAs from 438
human pre-miRNAs and eight viral pre-miRNAs that were
expressed in the four LCLs (Tables S2-S5).
The most abundant cellular miRNAs expressed in LCLs
included miR-21, let-7(a-i), miR-142, miR-155, miR-103, miR-
320a/b/c/d, and miR-146a/b (Figure 1A–D). Together, these
miRNAs accounted for ,50% of all miRNAs detected. Notably,
high expression for many of these cellular miRNAs is congruent
with other miRNA profiling studies done with EBV-infected B
cells [13,40,41]. For example, elevated levels of miR-21, miR-155,
miR-146a, and miR-146b have been reported in EBV+ LCLs and
BL cells in type III latency and induction of miR-146a via NFkB
Author Summary
Over 90% of adults worldwide are infected with Epstein-
Barr virus (EBV). While EBV infection is normally controlled
by a healthy immune system, in immuno-compromised
individuals, EBV can cause serious disease and/or cancer.
During infection, EBV expresses viral microRNAs (miRNAs)
and induces the expression of specific cellular miRNAs. In
general, miRNAs inhibit target gene expression by binding
to complementary regions on target messenger RNAs
(mRNA). While cellular miRNAs regulate important biolog-
ical processes such as cell growth and differentiation, and
many miRNAs have been linked to cancer progression, the
functions of EBV miRNAs are largely unknown. To identify
targets of EBV miRNAs and cellular miRNAs in EBV-infected
cells, we used a high-throughput method based on next-
generation sequencing technology to give a global picture
of miRNA-regulated gene expression. Our analysis showed
that over 500 mRNAs can be regulated by viral miRNAs,
many of which are directly relevant to EBV infection. This
study provides a comprehensive survey of viral and cellular
miRNA targets in B cells, which is a positive step towards
identifying novel therapeutic targets for EBV-associated
cancers.
The LCL miRNA Targetome
PLoS Pathogens | www.plospathogens.org 2 January 2012 | Volume 8 | Issue 1 | e1002484Figure 1. Cellular and viral miRNAs detected in LCLs by deep sequencing. A–D. miRNAs present in four LCLs (EF3D-AGO2, LCL35, LCL-BAC,
SDLCL) were detected by deep sequencing. Shown is the distribution of reads mapping to cellular (orange, grey) and viral (dark blue) pre-miRNAs; the
most abundant cellular miRNAs are highlighted. miR-17/92 includes reads mapping to miR-17, 18a, 19, 20a, and 92a. E. EBV miRNA expression as
determined by deep sequencing. Read counts were normalized to the total number of reads mapping to pre-miRNAs in each library. F. Primer
extension analysis detects six EBV miRNAs expressed in EF3D-AGO2.
doi:10.1371/journal.ppat.1002484.g001
The LCL miRNA Targetome
PLoS Pathogens | www.plospathogens.org 3 January 2012 | Volume 8 | Issue 1 | e1002484activation has been linked to LMP1 expression [13,14]. Moreover,
EBV infection strongly stimulates miR-155 expression, which is
critical for the growth of LCLs in vitro [13–15,20,41-43].
EBV-encoded miRNAs accounted for 7-22% of the total
miRNAs expressed in LCLs (Figure 1A–D). Ten mature miRNAs
originating from all eight EBV pre-miRNAs encoded by the B95-8
strain were identified (Table 1; Fig. 1E). We also detected low
levels of miRNA passenger strands, including miR-BART15-5p,
miR-BART2-3p, and miR-BART4-3p (Tables S2-S5). Consistent
with the latency III gene expression pattern in LCLs, we detected
all BHRF1 miRNAs, which arise from Cp/Wp-initiated latent
transcripts [3,8]. Although BART miRNAs are predominantly
expressed at high levels during latency II, such as in EBV-
associated nasopharyngeal carcinomas (NPC) and NPC-derived
cells [3,5,6], we also detected miRNAs from all five EBV-B95-8
BART pre-miRNAs, congruent with previous reports indicating
that the BART miRNAs are expressed in all stages of EBV latency
[7,8]. Based on read counts, miR-BHRF1-1 and miR-BART1-5p
were expressed at higher levels than other EBV miRNAs (Tables
S2-S5, Figure 1E). We confirmed the expression of six different
EBV miRNAs by primer extension analysis (Figure 1F).
Minor sequence variations occurred at the 39 ends of both the
viral and cellular miRNAs, which is consistent with other reports
on miRNA deep sequencing of c-herpesvirus-infected cells [44–
47]. The 59 ends were precise for all detected viral miRNAs
(Table 1) as well as for the majority of cellular miRNAs; however,
59 nt variations were observed for a few cellular miRNAs (i.e. miR-
140-3p, miR-142-3p, miR-10a) (Tables S2–S5). Primary tran-
scripts for miR-BHRF1-1 and other EBV miRNAs were
previously reported to undergo adenosine (A) to inosine (I) editing
[36]; indeed, one recent study estimated that 20% of human pri-
miRNAs may be subjected to A to I editing by ADARs and can
directly influence miRNA targeting [48]. Therefore, we also
examined all reads mapping to EBV and cellular pre-miRNAs for
A.G substitutions, but found no evidence of A to I editing in any
mature viral miRNA sequences (data not shown).
Identification of Ago2 binding sites using PAR-CLIP
Having established the EBV-B95-8 LCL miRNA transcrip-
tome, we next sought to determine the targets for all viral and
cellular miRNAs expressed in LCLs during latent EBV infection.
To capture miRNA:mRNA target interactions in a comprehensive
and high-throughput manner, we implemented the PAR-CLIP
method combined with computational analysis to directly identify
RISC-bound mRNAs [49,50]. Using this method, we analyzed
three of the four ‘‘wild-type’’ EBV-B95-8 LCLs from Figure 1
(EF3D-AGO2 (stably expressing a FLAG-tagged version of Ago2),
LCL35, and LCL-BAC) and two additional LCLs, LCL-BAC-D1
and LCL-BAC-D3, infected with miRNA-knockout viruses lacking
miR-BHRF1-1 or miR-BHRF1-3, respectively (Table S1). These
miRNA-knockout viruses, and the phenotypes associated with
mutational inactivation of the individual BHRF1 miRNAs, have
been previously described [32].
LCLs were cultured in the presence of 4-thiouridine (4SU), a
photoactivatable ribonucleoside analog which is readily taken up
by cells and incorporated into nascent RNAs. The cells were then
UV irradiated at 365 nm to cross-link RISC-bound RNAs. Cross-
linked RNAs were immunopurified using either anti-FLAG
(EF3D-AGO2) or anti-Ago2 antibodies (remaining four LCLs),
digested with RNAse T1, and reverse transcribed to cDNA for
deep sequencing. The incorporation of 4SU into nascent RNAs is
a key component of PAR-CLIP. During reverse transcription,
4SU favors pairing with guanine (G) and consequently, is
converted to a cytosine (C) during PCR amplification. Thus, in
the final sequencing reads, a thymine to cytosine (T.C)
conversion marks the cross-linked site, and generally, these T.C
conversions occur 39 or 59 to a miRNA seed match site [49,50].
Over 46 million reads were obtained from the five LCL PAR-
CLIP libraries, and 10.3 million reads aligned at one unique
location to either the human or EBV genome (Table S1). In order
to extract as much information as possible from our sequencing
data, we allowed for up to three mismatches including T.C
conversions in our alignments. To identify miRNA-targeted
regions, we used the PARalyzer toolkit, described in detail
elsewhere [49]. Briefly, reads were grouped according to genomic
location and read clusters with T.C signals above background
were analyzed for canonical miRNA seed match sites. Such
clusters represent miRNA:mRNA interaction sites, and unless
otherwise noted, these sites minimally include: 7mer (nt 2-8) and
7mer1A (nt 2-7 with an A across from position one of the mature
miRNA) seed matches [10,11]. Compared to previous clustering
strategies [50], our analysis of PAR-CLIP reads leads to a better
resolution of miRNA binding sites, particularly those in close
proximity to each other. For example, in EF3D-AGO2, the
BACH1 39UTR has at least 22 mapped clusters (Table S10), four
of which are separated by # 12 nt and, using our approach, could
be assigned to different targeting miRNAs (Table S10).
Clusters are 39UTR biased and preferentially distributed
towards 39UTR termini
A total of 153,007 clusters were identified in all five PAR-CLIP
libraries (Table S1), and 40.3% of these clusters were detected in at
least two of the five libraries (Figure S1). We were encouraged by
this high level of cluster overlap given the fact that the five LCLs
were (i) generated from different donors, (ii) in culture for different
lengths of time, (iii) infected with EBV B95-8, EBV B95-8-derived
Bacmid, or BHRF1 miRNA mutant viruses, and (iv) the Ago2
immunoprecipitations were performed with different antibodies
(i.e. anti-FLAG antibody vs antibody to endogenous Ago2).
Interestingly, we observed greater cluster overlap for LCL-BAC
and LCL-BAC-D1 compared to the other three libraries (Figure
Table 1. Predominant isoforms of EBV miRNAs as detected
by deep sequencing.
miRNA Sequence
ebv-mir-bart1-5p TCTTAGTGGAAGTGACGTGCTGTG(A)
ebv-mir-bart1-3p TAGCACCGCTATCCACTATGTC
ebv-mir-bart15-5p (*) AGGGAAACATGACCACCTGAAGTCT
ebv-mir-bart15-3p GTCAGTGGTTTTGTTTCCTTGA
ebv-mir-bart2-5p TATTTTCTGCATTCGCCCTTGC
ebv-mir-bart2-3p (*) AAGGAGCGATTTGGAGAAAATAAA
ebv-mir-bart3-5p (*) ACCTAGTGTTAGTGTTGTGCTG
ebv-mir-bart3-3p CGCACCACTAGTCACCAGGTGT
ebv-mir-bart4-5p GACCTGATGCTGCTGGTGTGC(T)
ebv-mir-bart4-3p (*) CACATCACGTAGGCACCAGGTGT
ebv-mir-bhrf1-1 TAACCTGATCAGCCCCGGAGTT(G)
ebv-mir-bhrf1-2-5p AAATTCTGTTGCAGCAGATAGC
ebv-mir-bhrf1-2-3p TATCTTTTGCGGCAGAAATTGA
ebv-mir-bhrf1-3 TAACGGGAAGTGTGTAAGCACA
(*) indicates the miRNA was previously annotated as the miRNA* or passenger
strand and by deep sequencing here, accounts for less than 5% of the total
reads mapping to the pre-miRNA. ebv-mir-bart1-3p and ebv-mir-bhrf1-2-3p
were previously annotated in miRBase as miRNA* but do not meet the criteria.
doi:10.1371/journal.ppat.1002484.t001
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aligned reads and, therefore, fewer clusters than the other libraries
(Table S1), a greater percentage of their clusters were detectable in
other libraries. This suggests that the partial overlap observed for
individual libraries may be due to non-saturating sequencing
depth (despite the fact that we obtained a minimum of five million
reads per sample using the then available deep sequencing
technology).
To further investigate clusters that were identified in multiple
libraries, we plotted the average read count for each cluster against
the number of libraries containing that cluster (Figure S1C).
Clusters with higher read counts were captured more consistently
in multiple PAR-CLIP libraries than clusters with lower read
counts. Interestingly, we observed a similar correlation when we
plotted clusters that could be assigned to a targeting miRNA (see
below) against miRNA expression level (Figure S1D). Clusters with
seed matches to highly expressed miRNAs were captured more
consistently in multiple PAR-CLIP libraries than clusters with seed
matches to weakly expressed miRNAs. Together, these data
suggest that clusters present in only a single library are more likely
to represent interactions between low expressed miRNAs and
mRNAs, weak miRNA:mRNA interactions, or possibly interac-
tions between miRNAs and low expressed mRNAs, although we
cannot rule out transient interactions. Furthermore, clusters
present in multiple libraries are more likely to represent
miRNA:mRNA interactions between highly expressed miRNAs
and strong target sites on mRNAs. Based on these results, we
focused our analysis on clusters that were present in at least two of
the five libraries.
The 153,007 clusters identified in all five PAR-CLIP libraries
represent ,23,000 unique CLIPed sites that were present in at
least two of the five libraries. Clusters varied in length, between 8
nt to ,200 nt, with .95% of clusters between 18–31 nt in length
(Tables S10–S14), and mapped to 39UTRs, coding regions,
59UTRs, introns, miRNAs, and intergenic regions. Congruent
with previous reports showing that miRNAs predominantly act on
39UTRs [10,48], we found that clusters mapping to regions that
were identified in multiple PAR-CLIP libraries were biased toward
39UTRs (Figure 2A). Of the ,23,000 CLIPed sites present in at
least two of the five libraries, 32.6% mapped to cellular 39UTRs.
The percent of CLIPed sites mapping to 39UTRs increased to
35.0% and 44.3% when we examined CLIPed sites present in at
least three and four libraries, respectively. Of the 2,062 CLIPed
sites that were common to all five of the libraries, 53.8% mapped
Figure 2. Distribution of PAR-CLIP Clusters reveals 39UTR bias. A. Overlap of clusters in the five PAR-CLIP libraries. Shown is the breakdown of
clusters mapping to 39UTRs, 59UTRs, coding regions (CDS), intergenic regions, introns, and mature miRNAs. Clusters from separate libraries were
considered overlapping if, based on genome coordinates, they shared .50% of their nucleotides. B. miRNA-interaction 39UTR sites specific to EBV-
infected LCLs. miRNA-interaction sites present in at least two of the five LCL PAR-CLIP libraries were compared to miRNA-interaction sites present in
two EBV-negative PEL PAR-CLIP libraries. 109 sites in 39UTRs contain seed matches to only EBV miRNAs and are highly specific to EBV-infected LCLs. C
and D. Breakdown of 39UTR (C) and CDS (D) sites assigned to individual EBV miRNAs.
doi:10.1371/journal.ppat.1002484.g002
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regions (CDS) and 0.7% that mapped to 59UTRs (Figure 2A). A
limited number of valid miRNA binding sites for viral miRNAs
have previously been identified in coding regions and 59UTRs
[51,52]; therefore, a subset of clusters mapping to these regions
may indeed represent functional miRNA:mRNA interactions.
Prior computational studies predicted that miRNAs not only
preferentially target 39UTRs, but also tend to bind sites located
near the termini of 39UTRs [53,54]; therefore, we plotted the
number of observed clusters against their relative position in a
39UTR. In agreement with these prior predictions, clusters were
generally distributed towards the start and end of 39UTRs,
demonstrating a preference for miRNA binding site positioning
(Figure S1B and data not shown).
EBV-specific miRNA target sites
Based on seed sequence complementarity, 68.6% of all clusters
(including 39UTRs, 59UTRs, CDS, and intergenic regions) could
be assigned to a miRNA that was present in a matched deep
sequencing library (Table S1; Tables S10–S14). A total of 7,827
39UTR miRNA-interaction sites were present in at least two
libraries, representing 3,492 different 39UTRs (Table S6). As an
additional filter, we required that the miRNAs assigned to these
sites to be represented in at least two of the five small RNA
libraries (Tables S2–S5; data not shown). 6,029 (77.0%) of the
7,827 39UTR sites could be assigned to a miRNA. We identified
an additional 2,972 CDS miRNA-interaction sites present in at
least two libraries, 89.7% of which could be assigned to a miRNA
(Table S7).
To place more stringency on our data and isolate a set of miRNA
targets specific to EBV-infected LCLs, we compared the five LCL
PAR-CLIPlibrariestofourPAR-CLIPlibrariesgeneratedfromtwo
B cell primary effusion lymphomas (PEL) that are EBV-negative
[55]. 47.3% of the 39UTR miRNA-interaction sites in LCLs
overlapped with clusters generated from the EBV-negative PEL
PAR-CLIP libraries (Figure 2B). This amount of overlap was
expected since the cellular miRNAs expressed in LCLs and PELs
are similar [40,44,55]. 52.7% (4,128) of the 39UTR sites identified
in LCLs were specific to EBV-infected LCLs (Table S6, Figure 2B).
We next examined EBV miRNA-targeted sites. 531 (16.2%) of
the 7,827 39UTR miRNA-interaction sites contained seed matches
to EBV-B95-8 miRNAs. These 531 sites were present in 494
different 39UTRs (Table S6). Furthermore, of the miRNA-
interaction sites assigned to EBV miRNAs, 70.2% (373 out of
531 sites) were specific to EBV-infected LCLs and therefore,
represent high-confidence target sites. A subset of the remaining
EBV miRNA-interaction sites that overlapped with the PEL PAR-
CLIP libraries can be explained by the fact that EBV miR-
BART1-3p shares seed homology (nt 2-7) to cellular miR-29a/b,
which is expressed in both LCLs and PEL (Figure 3D; Table S2-
S5) [40,44,55]. Consequently, a number of miRNA-interaction
sites assigned to miR-BART1-3p are also assigned to miR-29a/b
(Tables S6, S7, S10–S14). In fact, a large proportion of the
miRNA-interaction sites assigned to EBV miRNAs could also be
assigned to cellular miRNAs; however, the sites that were assigned
to both viral and cellular miRNAs were, on average, longer than
the sites assigned only to viral miRNAs (Table S6), and therefore,
could potentially represent adjacent miRNA binding sites within a
RISC-accessible region on a target mRNA. We identified 129
miRNA-interaction sites that contained canonical seed matches
for only EBV miRNAs, and could not be assigned to any cellular
miRNAs. Of these 129 sites, 109 (84.5%) were specific to EBV
LCLs, and thus represent a highly stringent set of EBV-specific,
EBV miRNA targets (Figure 2B; Table S6).
Figure 2C shows the breakdown of the 531 39UTR sites
assigned to individual EBV miRNAs. We identified putative
39UTR target sites for all highly expressed EBV miRNAs
(Figure 2C). We also identified sites for miR-BART2-3p, miR-
BART3-5p, and miR-BART4-3p, which are all annotated as
miRNA passenger strands (miRNA*) (Tables S2–S5); however,
these miRNA*s showed significantly fewer seed matches to PAR-
CLIP clusters than the mature EBV miRNAs (Figure 2C).
Individual EBV miRNAs had on average ,40 high-confidence
target sites in 39UTRs, ranging from 14 target sites for miR-
BHRF1-3 to 88 target sites for miR-BART2-5p (Figure 2C). We
also observed clusters in coding regions with seed matches to viral
miRNAs, although compared to 39UTR sites, the overall number
of assigned CDS sites was substantially lower (Figure 2D). In
contrast to the previously reported 44 candidate EBV miRNA
targets [35], which represent only ,1% of the potential EBV
miRNA targetome, the number of PAR-CLIP identified EBV
miRNA seed match sites is much closer to bioinformatic
predictions [39] arguing that individual miRNAs can target more
than 100 different mRNAs. Thus, including 39UTR sites, CDS
sites, and sites with seed matches to EBV miRNA*s, which are all
functional in certain settings [56,57], the PAR-CLIP-identified
EBV-B95-8-miRNA targetome consists of a total of 630 different
cellular mRNAs.
The majority of miRNA-interaction sites mapped to cellular,
not viral, transcripts, and contained potential seed match sites for
either viral or cellular miRNAs (Tables S10–S14). In fact, ,0.2%
of sites mapped to the EBV genome (discussed below), none of
which contained seed match sites for any of the EBV miRNAs.
Thus, EBV-B95-8 miRNAs appear to exclusively target cellular
transcripts during latent infection, in support of a scenario in
which EBV miRNAs facilitate reprogramming of the cellular
environment to establish and/or maintain latency.
PAR-CLIP identifies previously reported miRNA targets
To validate PAR-CLIP-identified targets, we initially queried
our data for previously published miRNA targets. First, we
examined the Ago2-based RIP-ChIP dataset from Do ¨lken et. al.
[35]. These investigators reported 2,337 genes that were enriched
in Ago2-immunoprecipitations from six different human B cell
lines [35]. Since all of these genes may not be expressed in LCLs,
we therefore focused on genes with detectable clusters present in at
least two PAR-CLIP libraries. 1,252 genes of the 2,337 genes were
represented in the LCL PAR-CLIP libraries. Of these 1,252
represented genes, 91.9% had high-confidence PAR-CLIP-
identified miRNA seed match sites (minimum 7mer1A) in their
39UTRs or CDSs (Tables S6, S7). These results indicate that
PAR-CLIP indeed captures a large proportion of previously
reported B cell miRNA:mRNA interactions (Figure S2A–C).
We next focused on a single cellular miRNA, miR-155, which is
implicated in a number of B cell malignancies. miR-155 is among
the most highly expressed cellular miRNAs in LCLs (Figure 1) and
is essential for the growth of LCLs in vitro [20]. Additionally, miR-
155 targets are important to oncogenic herpesvirus biology as
both KSHV and MDV encode functional miR-155 analogs
[21,22,23,24]. In terms of cellular mRNA targets, miR-155 has
been extensively characterized by a number of different approach-
es, including microarray and proteomics approaches, either
through over-expression or knockdown [21,22,58–61]. Although
these prior studies were performed on a variety of different cell
types (i.e. epithelial versus B cells) and backgrounds (i.e. mice
versus human), and therefore represent a diverse set of miR-155
targets that may not be specific to LCLs, we nevertheless compiled
a list of reported miR-155 targets (493 total candidate and
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miR-155-assigned miRNA interaction sites (363 sites representing
349 39UTRs) presented in Table S6. 84 (24.1%) of the miR-155-
assigned 39UTRs identified by PAR-CLIP were previously
reported as potential miR-155 targets (Figure S2D and Table
S8). This number rose to 93 when we included high-confidence
miR-155-assigned CDS sites from Table S7. We identified 23 of
the top 100 miR-155-affected genes determined by pSILAC [58]
and 45 of the 149 miR-155 target 39UTRs examined by Xu et. al.
using luciferase reporter assays [60] (Table S15). We also
compared our PAR-CLIP miR-155-assigned targets to in silico
target predictions. TargetScan (v5.1) predicted that 241 (69%) of
the 349 miR-155-assigned 39UTRs were targets of miR-155
[11,39,53] (Table S8 and data not shown).
Next, we investigated previously reported targets of EBV
miRNAs. To date, 52 candidate targets of EBV miRNAs have
been proposed, ten of which have been further validated by
luciferase reporters or functional assays [4,27–31,35–38]. We
identified EBV miRNA binding sites (minimum nt 2-7 seed match)
in the 39UTRs of 14 of the 44 candidate EBV target genes
reported by Do ¨lken et. al.; however, only three of these
miRNA:mRNA interactions met our stringent criteria outlined
above of being present in at least two libraries with a minimal seed
match of 7mer1A (Table S9). The remaining 30 candidate EBV
targets may contain seed match sites for the 17 BART miRNAs
that are not encoded by EBV B95-8. Five of the ten validated EBV
miRNA targets were identified in PAR-CLIP clusters (Tables S10-
14), and of these, one target, IPO7, was confirmed as a target of
miR-BART3 (Table S9). We also identified the pro-apoptotic
tumor suppressor Bim (BCL2L11) as a putative target of miR-
BART4 and miR-BART15. Bim was previously reported to be
targeted by multiple BART miRNAs [38]. Interestingly, APAF1, a
component of the apoptosome, was identified as a strong
candidate, EBV-specific target of EBV miR-BART3-3p (Table
S6). This further supports a pro-survival, anti-apoptotic role for
EBV miRNAs, as previously suggested [37,38].
MICB and DICER1 were both identified by PAR-CLIP as
EBV miRNA targets; however, we identified different miRNAs
with seed matches to clusters mapping to these 39UTRs than what
has been previously reported. DICER1 is a reported target of
miR-BART6 [36], which is deleted in EBV B95-8. Therefore, we
can only say that DICER1 is likely targeted by additional EBV
miRNAs, including miR-BART1-5p, miR-BART1-3p, miR-
BART3-3p, and miR-BHRF1-1 (Table S9). miR-BART2-5p,
which is reported to target MICB [28], is expressed in EBV B95-8
LCLs; however, we did not identify any clusters near the reported
miR-BART2-5p binding site in any of the five PAR-CLIP
libraries. Instead, we identified seed match sites for miR-BART3
and miR-BART1-3p (Table S9). The reasons for this discrepancy
are unclear, but potentially include cell type differences or limits in
sequencing depth.
The two remaining cellular genes reportedly targeted by EBV
miRNAs, CXCL11 and PUMA, are not detectably expressed in
LCLs [29,37,62]. However, we did identify a miR-BART1-3p
seed match site in the CXCL10 39UTR (Table S6), which, like
CXCL11, is one of three chemokines and T cell attractants that
activates the CXCR3 receptor on T cells [29].
PAR-CLIP identifies functional miRNA targets
To experimentally validate miRNA targets, we cloned 13 PAR-
CLIP-identified target 39UTRs into luciferase vectors and
performed dual luciferase reporter assays following ectopic viral
or cellular miRNA expression in 293T cells. These 13 diverse
39UTRs (i) were identified as putative EBV miRNA targets in at
least two of the five PAR-CLIP libraries, (ii) contained seed match
site(s) for at least one EBV miRNA, and (iii) represent targets of
potential interest to EBV biology.
We tested eleven miRNA expression vectors, including six viral
miRNAs (miR-BART1, miR-BART2, miR-BART3, miR-
BART4, miR-BHRF1-1, and miR-BHRF1-2) and five cellular
miRNAs or miRNA clusters (miR-155, miR-146a, miR-128, miR-
17/92, and miR-106b/25) against the panel of 39UTRs. A total of
106 miRNA:39UTR combinations were tested, 29 of which were
identified by PAR-CLIP (Figure 3A, red bars); the other 77
combinations tested served as controls. We observed significant
knockdown (.20%) of luciferase expression for 21 out of the 29
(72.4%) PAR-CLIP-identified miRNA:39UTR pairs, confirming
these 39UTRs as functional miRNA targets. Three additional
PAR-CLIP-identified miRNA:39UTR combinations showed mod-
est but statistically significant knockdown (p,0.05, Figure S3),
indicating that ,83% of assigned miRNA:39UTR interactions are
functional. Five of the 29 PAR-CLIP-identified miRNA:39UTR
pairs showed no knockdown. Thus, using our approach, we can
correctly identify a functional miRNA-binding site and the
targeting miRNA in ,75% of cases.
In total, 32 miRNA:39UTR pairs resulted in .20% luciferase
knockdown. Sequence analysis of these 39UTRs revealed that, in
addition to the 21 PAR-CLIP-identified miRNA binding sites,
eight seed matches to tested miRNAs were present, which likely
explain the observed knockdown (nt 2-7 seed match) (Figure 3A,
black bars). However, the presence of a seed match alone was not
enough to result in luciferase knockdown. In fact, 59 of the 106
assayed miRNA:39UTR combinations harbored seed matches,
and 27 (46%) of these 59 combinations did not result in any
knockdown. Furthermore, when we ranked the miRNA:39UTR
combinations by increasing level of knockdown from left to right
(Figure 3A), we find that PAR-CLIP-identified combinations (red
bars) cluster together towards the right, while miRNA:39UTR
combinations harboring only seed matches (black bars) are more
randomly distributed. These results clearly demonstrate that PAR-
CLIP effectively captures functional miRNA target sites.
Three miRNA:39UTR combinations that were not assigned by
PAR-CLIP and lacked miRNA seed matches also resulted in
Figure 3. Luciferase reporter assays confirm miRNA-targeted 39UTRs identified by PAR-CLIP. A. 39UTRs for 13 genes were inserted into
the 39UTR of firefly luciferase and tested against 11 different miRNA expression vectors for a total of 106 miRNA:39UTR pairs. 39UTR reporter plasmids
were co-transfected into 293T cells with either EBV or cellular miRNA expression plasmids; lysates were assayed for luciferase activity. All values are
relative to an internal renilla luciferase control and then, normalized to luciferase GL3 vector control (no 39UTR) shown in Figure S3. Reported are the
averages of two to five independent experiments performed in triplicates. PAR-CLIP-identified miRNA:mRNA interactions are highlighted in red.
39UTRs containing a minimal 6mer seed match (nt 2-7) to the assayed miRNA but not identified by PAR-CLIP are shown in black. 32 miRNA:mRNA
pairs resulted in .20% luciferase knockdown and are highlighted on the right. B and C. PAR-CLIP identified seed match sites in select 39UTRs for BART
miRNAs were mutated to NheI restriction enzyme sites in the luciferase reporter vectors to disrupt miRNA binding. Both the LY75 and DAZAP2 39UTRs
contain two PAR-CLIP-identified sites for miR-BART1-5p and miR-BART3-3p, respectively, and only the site with the highest read count was mutated.
Luciferase assays were performed as in (A) and values are shown relative to an internal renilla luciferase control. D. Alignment of miR-BART3-3p, miR-
BART1-3p, and cellular miR-29a, which share sequence homology.
doi:10.1371/journal.ppat.1002484.g003
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whether non-canonical miRNA targeting might explain the
knockdown, we investigated clusters mapping to these three
39UTRs for potential miRNA target sites using RNAhybrid to
calculate binding energy and extent of pairing [63]. We identified
two miRNA:39UTR pairs that exhibited single G:U base pairs in
the seed region (miR-BART3-3p/PELI1; miR-BART3-3p/
PDE7A). Furthermore, both of these sites with predicted G:U
pairs occurred at locations that coincided with PAR-CLIP clusters
not assigned to any miRNAs, indicating that these are likely
genuine EBV miRNA target sites (data not shown).
Of the 12 PAR-CLIP-identified target 39UTRs tested against
EBV miRNAs, 11 39UTRs (BACH1, CLEC2D, CLIP1, DA-
ZAP2, KDM4B, LY75, OTUD1, PDE7A, PELI1, SP100,
ZNF451) resulted in luciferase inhibition following ectopic viral
miRNA expression (Figure S3). These 11 experimentally validated
EBV miRNA target genes more than double the current list of
reported EBV miRNA targets, making this the largest set of
validated EBV miRNA targets to date. Five of the 39UTRs,
including BACH1, CLEC2D, LY75, OTUD1, and PDE7A, were
targeted by more than one EBV miRNA. Among these, BACH1,
a published target of miR-155 and KSHV miR-K11 [21,22], can
also be targeted by multiple EBV miRNAs (Figure S3).
Interestingly, we identified seed matches for both the 3p and 5p
strands of miR-BHRF1-2 in clusters mapping to the BACH1
39UTR, although these sites were identified in only the EF3D-
AGO2 PAR-CLIP library (Table S10). Mutational studies on the
BACH1 39UTR indicate that some of these identified binding sites
for miR-BHRF1-2 are in fact functional (J.G. Powers and B.R.
Cullen, unpublished observations).
To demonstrate that the knockdown of luciferase expression is
indeed due to a miRNA:target site interaction, we mutated the
seed match sites for BART1 and BART3 miRNAs in four cellular
39UTRs (SP100, LY75, CLEC2D, DAZAP2). LY75 and DA-
ZAP2 have two PAR-CLIP-identified sites assigned to miR-
BART1-5p and miR-BART3-3p, respectively (Table S6); there-
fore, we mutated the sites with the greatest read counts (Tables
S10–S14). With the exception of DAZAP2, mutation of the
individual seed match sites fully abrogated the miRNA effect on
the reporters (Figure 3B–C). Mutation of the major miR-BART3-
3p-assigned site in DAZAP2 only partially relieved the inhibitory
effect of BART3 on this 39UTR (Figure 3C), suggesting that the
second PAR-CLIP-identified site for miR-BART3-3p (Table S6)
may further contribute to the targeting of this 39UTR.
Interestingly, the CLEC2D 39UTR contains a short stretch of
nucleotides that can be occupied by either miR-BART1-3p or
miR-BART3-3p and mutation of this single site abrogates miRNA
activity for both of these EBV miRNAs (Figure 3B–C). This result
is explained by the partial seed homology shared by miR-BART1-
3p and miR-BART3-3p (Figure 3D). In contrast, the DAZAP2
39UTR, which is targeted by miR-BART3-3p, is not targeted by
this miRNA (Figure S3). These results demonstrate that miR-
BART1-3p and miR-BART3-3p can have overlapping as well as
distinct target mRNAs.
BHRF1 miRNA deletion mutants reveal high confidence
targets
Deletion of EBV BART miRNAs reportedly has little to no
effect on the outgrowth of LCLs in vitro; however, deletion of all
three BHRF1 miRNAs results in significant inhibition of LCL
outgrowth and proliferation and also affects EBV latent gene
expression [32–34]. Arguably, then, BHRF1 miRNAs are likely to
have targets that are involved in B cell transformation and/or the
establishment of latent EBV infection. We therefore focused on the
viral BHRF1 miRNAs and generated LCLs infected with miRNA-
knockout viruses lacking either miR-BHRF1-1 or miR-BHRF1-3.
These miRNA-knockout viruses, and the phenotypes associated
with mutational inactivation of the individual BHRF1 miRNAs,
have been described in detail elsewhere [32].
As described above, we generated PAR-CLIP libraries for LCL-
BAC-D1 (lacking miR-BHRF1-1) and LCL-BAC-D3 (lacking
miR-BHRF1-3). Small RNA deep sequencing libraries were
generated in parallel (data not shown). Deletion of either miR-
BHRF1-1 or miR-BHRF1-3 had no major effects on the
expression of other viral miRNAs as determined from deep
sequencing data (Figure 4D). To identify high confidence targets
for these two viral miRNAs, we compared 39UTR sites that were
assigned to each of these miRNAs in the five PAR-CLIP libraries
that were specific to EBV-infected LCLs (Table S6). We were
stringent in our analysis and required that sites assigned to miR-
BHRF1-1 be present in at least three out of the five libraries. 40
39UTR sites met these criteria (Figure 4A). As expected, 36 of the
39UTR sites were absent from the LCL-BAC-D1 library, and
therefore represent highly stringent, high confidence targets of
miR-BHRF1-1 (Figure 4A). For miR-BHRF1-3, only six target
39UTR sites were identified in three or more PAR-CLIP libraries.
When we lowered the cutoff to two or more libraries, a total of 13
39UTR sites were identified as miR-BHRF1-3 targets, and 11 of
these were absent from the LCL-BAC-D3 library. Together, these
data indicate that in ,89% of cases, the correct miRNA is
assigned to a PAR-CLIP-identified target site. This number is
comparable to the ,75% of miRNA target sites that were
correctly assigned as determined from the 106 miRNA:mRNA
combinations tested by luciferase reporter assays (Figure 3).
We selected three 39UTRs (GUF1, NAT12, and SCRN1) that
were identified as high confidence targets for miR-BHRF1-1 for
further analysis by luciferase reporter assays. Co-transfection of a
miR-BHRF1-1 expression plasmid with each 39UTR reporter
resulted in knockdown of luciferase expression (Figure 4E). This
knockdown was specific to the miR-BHRF1-1-assigned target
region since mutation of the seed match site (SCRN1) or deletion
of the target region (GUF1 and NAT12) abrogated the effect of
miR-BHRF1-1 (Figure 4E).
BHRF1 miRNAs use 59 canonical seeds for targeting
Surprisingly, miR-BHRF1-3 had only a few assigned target
39UTRs despite the fact that this miRNA was expressed at levels
comparable to miR-BHRF1-1 in LCL-BAC as detected by deep
sequencing (Figure 4D). Quantitative analysis of EBV miRNAs in
LCLs by qRT-PCR has also shown that the three BHRF1
miRNAs are expressed at similar copy numbers per cell [8]. Even
miR-BART2-5p and miR-BART15, which were ,50 times less
abundant than miR-BHRF1-3 according to read counts, had over
four times as many assigned target 39UTRs (Figures 2C and 4D).
We investigated whether miR-BHRF1-3 might target regions
other than 39UTRs, such as 59UTRs or coding regions (CDS);
however, there were no major differences in the distribution of
clusters for LCL-BAC-D3 compared to the other four libraries
(data not shown), and there was no preference in miR-BHRF1-3
seed match sites in CDS compared to 39UTRs (Figure 2).
We therefore examined PAR-CLIP clusters for miRNA binding
sites outside of the canonical 59 seed match site. We analyzed
strings of 6mers present in miR-BHRF1-1 and miR-BHRF1-3
sequences for perfect matches to PAR-CLIP-identified clusters.
Notably, we observed enrichment in matches to 6mers encom-
passing nt 1-6, 2-7, and 3-8 in all four LCLs expressing miR-
BHRF1-1 (Figures 1E, 4D, and 5B). As expected, there was a lack
of 6mer 59 seed matches to miR-BHRF1-1 specifically in the LCL-
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predominantly uses a canonical 59 seed of nt 2–7 or nt 2–8, or an
off-set 59 seed of nt 3-8, for mRNA targeting (Figure 5). We
extended our analysis to coding regions, which contain docu-
mented miRNA target sites [50,51,56]. A similar pattern of 59 seed
match enrichment was observed in LCLs expressing miR-BHRF1-
1; 21 clusters mapping to coding regions contained 59 canonical
seed matches to miR-BHRF1-1 and were absent from the LCL-
BAC-D1 library. Thus, miR-BHRF1-1 binds to CDS sites as well
as 39UTRs.
A slightly different pattern of 6mer matches was observed for
miR-BHRF1-3. 6mer matches were present in regions outside of
the canonical 59 seed match region, particularly between nt 6-13;
however, a similar number of matches to these regions were also
detected in clusters in the LCL-BAC-D3 library. Only the 59 seed
region showed the expected pattern: present in LCLs that express
Figure 4. High confidence targets of EBV miR-BHRF1-1 and miR-BHRF1-3. A. 39UTR clusters assigned to miR-BHRF1-1 (minimum seed
match: 7mer1A) that were present in at least three of the five PAR-CLIP libraries and are specific to EBV-infected LCLs are shown in red with annotated
gene symbols. Clusters that were absent from the LCL-BAC-D1 PAR-CLIP library are shown in white, and therefore, represent high confidence targets
for miR-BHRF1-1. The four miR-BHRF1-1-assigned clusters present in LCL-BAC-D1 can also be assigned to miR-BART4-5p. B. Similar to A, 39UTR clusters
assigned to miR-BHRF1-3 that were present in at least two PAR-CLIP libraries are shown in red; clusters absent from the LCL-BAC-D3 library are shown
in white. C. Alignment of miR-BHRF1-1 and miR-BART4-5p, which share an off-set seed sequence. D. EBV pre-miRNAs detected in LCL-BAC, LCL-BAC-
D1, and LCL-BAC-D3 as determined by deep sequencing. Reported are the total number of reads mapping to each EBV pre-miRNA. E. PAR-CLIP
identified seed match sites to miR-BHRF1-1 in three 39UTRs (***highlighted in A) were deleted (GUF1 and NAT12) or mutated to an NheI restriction
enzyme site (SCRN1) in luciferase reporter vectors to disrupt miRNA binding. Luciferase assays were performed as in Figure 3 and values are shown
relative to an internal renilla luciferase control.
doi:10.1371/journal.ppat.1002484.g004
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D3 (Figure 5C). We did not observe this pattern for coding
regions, suggesting that miR-BHRF1-3 targets are largely
restricted to 39UTRs. Since miR-BHRF1-3 contains three G’s
within the seed region (Figure 5A), we also investigated whether
this miRNA might use G:U pairing or contain a bulge in the seed
region, but did not observe any conditions which supported these
types of pairing (data not shown). Although we cannot rule out
other types of atypical miRNA pairing, these data indicate that
miR-BHRF1-3 predominantly uses a canonical 59 seed (mini-
mally nt 2-8) to target 39UTRs. It is possible that the low target
numbers observed might be due to an unfavorable stoichiometric
ratio between miR-BHRF1-3 and a small number of high-affinity
target mRNAs.
Redundancy in EBV miRNA targeting
Interestingly, all four miR-BHRF1-1-assigned clusters present in
the LCL-BAC-D1 library (AP1S1, G3BP1, STOM, and UHMK1)
could also be assigned to miR-BART4 (Table S6 and data not
shown). In fact, of the 40 39UTRs shown in Figure 4A, 35 could be
also be assigned to miR-BART4 with a 6mer (nt 2-7) seed match;
however, in all instances, miR-BHRF1-1 exhibited more extensive
base pairing (data not shown). Analysis of these two miRNAs
revealed sequence identity between nt 3-9 of miR-BHRF1-1 and
nt 2-8 of miR-BART4 (Figure 4C). As miR-BART4 expression in
LCL-BAC-D1 was not significantly affected by deletion of miR-
BHRF1-1 (Figure 4D), and 36 clusters are absent in LCL-BAC-
D1, these 39UTRs likely represent bona fide miR-BHRF1-1
targets; however, this does not exclude these 39UTRs from also
Figure 5. BHRF1 miRNAs target cellular mRNAs through seed match pairing. Consecutive 6mer sequences were examined for pairing with
clusters mapping to 39UTRs and coding regions. A. Schematic showing the interrogated 6mers. The sequences for miR-BHRF1-1 and miR-BHRF1-3 are
shown below; highlighted in red are the regions of each miRNA that show enrichment over background in pairing with clusters (nt 1-8 for miR-
BHRF1-1 and nt 2-9 for miR-BHRF1-3). B. and C. 6mers from miR-BHRF1-1 and miR-BHRF1-3, respectively, were analyzed for matches to clusters in
39UTRs or CDSs. Enrichment for a match is indicated in red, while absence of a match is indicated in grey. Numbers below indicate the 6mer sequence
described in (A).
doi:10.1371/journal.ppat.1002484.g005
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additional miR-BART4-assigned targets present in LCL-BAC-
D1 could also be bound by miR-BHRF1-1 to some extent.
These observations prompted us to investigate whether
additional viral miRNAs might share common targets. We found
that miR-BART1-3p, which shares 100% seed sequence
homology with cellular miR-29a/b/c [46], and miR-BART3-
3p exhibit extensive sequence homology, sharing 14 out of 22
nucleotides (Figure 3D). Similar to miR-BHRF1-1 and miR-
BART4, miR-BART1-3p and miR-BART3-3p share an off-set
seed and consequently, a portion of the targets for miR-BART3-
3p can be assigned to both these miRNAs as well as cellular miR-
29a/b/c with a minimum seed match of nt 2-7 (data not shown).
At least some of these sites can be occupied by either miR-
BART1-3p or miR-BART3-3p. For example, we confirmed
CLEC2D (LLT1), a ligand for natural killer (NK) cells [64], as a
target for both of these viral miRNAs using luciferase reporter
assays (Figure 3D).
Cellular pathways targeted by EBV miRNAs
To identify pathways that are potentially regulated by EBV
miRNAs, we used PANTHER (Protein Analysis Through
Evolutionary Relationships) to examine cellular pathways enriched
for virally-targeted genes. Using either the full miRNA targetome
identified by PAR-CLIP or the human genome as a reference list,
we mapped genes that were assigned as putative targets of EBV
miRNAs (39UTR and/or CDS) in at least two of the five PAR-
CLIP libraries (Tables S6, S7). The top 20 cellular pathways
potentially targeted by EBV miRNAs are listed in Table 2. These
included p53 feedback pathways, B cell signaling, oxidative stress
response, and apoptosis, all of which are clearly relevant to EBV
infection. Based on this analysis, and further supported by the
diversity of high confidence targets that we identified for individual
BHRF1 miRNAs (Figure 5), it is evident that EBV miRNAs have
not evolved to target one specific cellular pathway and instead,
likely have multiple functions.
The miR-17/92 cluster targets viral transcripts
Previous studies have reported that the latent viral transcripts,
LMP1 and LMP2A, are targeted by BART miRNAs [30,31]. To
determine whether additional viral transcripts might be regulated
by miRNAs, we aligned PAR-CLIP reads to the EBV B95-8
genome. Almost all of the reads mapped to latent transcripts,
including non-coding RNAs such as EBV pre-miRNAs and
EBERs (not shown), consistent with the pattern of latent viral gene
expression in LCLs (Figure 6A). In fact, we did not identify reads
mapping to lytic transcripts, such as BALF5, a published target of
miR-BART2-5p [4,27]. Three major miRNA-targeted regions
Table 2. Pathways targeted by EBV-B95-8 miRNAs.
# Ref. Genes EBV miRNA-targeted 39UTRs EBV miRNA-targeted 39UTRs and CDS
Pathways HG PC # genes P value vs HG P value vs PC # genes P value vs HG P value vs PC
p53 pathway feedback loops 2 52 51 9 7.40E-06 5.23E-04 12 1.49E-07 4.42E-05
T cell activation 102 88 11 5.76E-05 2.14E-03 13 2.82E-05 1.77E-03
B cell activation 82 65 9 2.35E-04 2.72E-03 9 1.32E-03 1.25E-02
p53 pathway 113 104 11 1.40E-04 7.28E-03 13 7.84E-05 6.99E-03
Interleukin signaling pathway 161 104 10 7.19E-03 1.86E-02 10 3.26E-02 7.31E-02
PDGF signaling pathway 159 139 12 6.89E-04 2.23E-02 13 1.84E-03 5.43E-02
Integrin signaling pathway 181 139 12 2.03E-03 2.23E-02 13 5.40E-03 5.43E-02
p53 pathway by glucose
deprivation
25 24 4 3.58E-03 2.26E-02 4 8.36E-03 4.81E-02
Parkinson disease 100 88 8 3.68E-03 4.35E-02 9 4.84E-03 6.41E-02
Coenzyme A biosynthesis 6 8 2 9.79E-03 4.92E-02 2 1.55E-02 7.54E-02
Cell cycle 22 19 3 1.75E-02 5.28E-02 3 3.27E-02 9.32E-02
Inflammation mediated by
chemokine and cytokine
signaling pathway
283 203 14 1.14E-02 6.93E-02 16 1.86E-02 1.15E-01
PI3 kinase pathway 115 81 7 2.48E-02 7.00E-02 9 1.14E-02 4.23E-02
Ubiquitin proteasome pathway 70 67 6 8.21E-03 7.86E-02 6 2.42E-02 1.79E-01
General transcription by RNA
polymerase I
20 11 2 8.72E-02 8.55E-02 2 1.30E-01 1.28E-01
Interferon-gamma signaling
pathway
29 24 3 3.53E-02 9.10E-02 3 6.39E-02 1.54E-01
Insulin/IGF pathway-protein
kinase B signaling cascade
35 59 5 5.59E-02 1.22E-01 7 9.84E-02 5.17E-02
Apoptosis signaling pathway 123 112 8 1.20E-02 1.26E-01 8 4.21E-02 2.98E-01
Ras Pathway 79 77 6 1.42E-02 1.28E-01 6 3.98E-02 2.68E-01
Hypoxia response via HIF
activation
32 29 3 4.51E-02 1.38E-01 4 1.90E-02 8.29E-02
HG = Homo sapien genes (19,911 total mapped genes).
PC = PAR-CLIP genes detected in one or more libraries (11,057 total mapped genes).
doi:10.1371/journal.ppat.1002484.t002
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PLoS Pathogens | www.plospathogens.org 12 January 2012 | Volume 8 | Issue 1 | e1002484Figure 6. LMP1 is targeted by the miR-17/92 cluster. A. EBNA2, BHRF1, and LMP1 transcripts are targeted by miRNAs in LCLs. Shown are
clusters mapping to the EBV B95-8 genome in three PAR-CLIP libraries. Clusters mapping to non-coding RNAs are not shown. B. Multiple Ago2-
interaction sites are present in the LMP1 39UTR. Shown are read groups (grey), clusters (orange), and T.C conversions (red) present in reads mapping
to the LMP1 39UTR in three PAR-CLIP libraries. C. The LMP1 39UTR contains an extensive seed match to the miR-17/20/106/93 family. Shown are the
mature miRNA sequences for miR-106a, miR-17, and miR-20a as identified by deep sequencing and the sequence of the LMP1 39UTR cluster
containing the seed match site. This site was also identified in LCL-BAC-D1 and LCL-BAC-D3 PAR-CLIP libraries (Tables S13 and S14). D. miR-17/92 and
miR-106b/25 inhibit the LMP1 39UTR reporter. The LMP1 39UTR luciferase reporter and renilla luciferase internal control vector were co-transfected
into 293T cells with indicated miRNA expression plasmids. *By Student9s t test, p,0.01 compared to vector control. E. Inhibition of endogenous miR-
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BHRF1, and the 39UTR of LMP1 (Figure 6A).
A total of seven potential miRNA-interaction sites were
identified in the LMP1 39UTR in at least two or more libraries
(Tables S10-S14). One of these sites contained a seed match for
the cellular miR-17/20/106/93 seed family and was detected in
all five PAR-CLIP libraries (Figure 6B-C, Tables S10-S14). miR-
17 and miR-20a are two of six miRNAs expressed from the miR-
17/92 cluster, while miR-106b and miR-93 are expressed from
the miR-106b/25 cluster [65,66]. Both miRNA clusters are
transcriptional targets of c-myc and are expressed in LCLs at
moderate to high levels (Tables S2-S5, Figure 1).
To investigate the interaction between the miR-17/20/106/93
seed family and the LMP1 39UTR, we generated a luciferase
reporter containing the full EBV LMP1 39UTR (pLSG-LMP1).
Over-expression of the miR-17/92 cluster or the miR-106b/25
cluster in 293T cells significantly decreased luciferase expression
from pLSG-LMP1, indicating these miRNAs are indeed targeting
the LMP1 39UTR (Figure 6D). To further confirm the miR-17/
20/106/93 interaction with the LMP1 39UTR, we introduced a
control sponge (sCXCR4) or a miR-17/20/106 sponge (s17/20/
106) into LCL35 to disrupt endogenous miRNA activity
(Figures 6E and S2). The miR-17/20/106 sponge contains nine
imperfect binding sites within the 39UTR of GFP for miR-17,
miR-20a, or miR-106a (Table S15); miR-106b and miR-93 differ
from these three miRNAs in their 39 non-seed sequences
(Figure 6C, Table S1-S4). Following transduction, cells were
sorted for high GFP expression, indicative of miRNA inhibition
[20], and then, cultured for one week. Western blot analysis of
LMP1 protein levels showed upregulation of LMP1 when the
activity of endogenous miR-17/20/106 family members was
inhibited (Figure 6F). We also observed upregulation of p21
(CDKN1A), a known target of miR-17/20/106 in B cells [66],
which we also confirmed as a miR-17/20/106 target by PAR-
CLIP (Tables S10-S14). Furthermore, we observed a ,4-fold
increase in the levels of LMP1 mRNA in miR-17/20/106-sponged
LCL35 compared to control cells by qRT-PCR; the levels of
EBNA2 mRNA were not affected (data not shown). Together,
these data show that the miR-17/20/106 family can target the
LMP1 39UTR in LCLs during latent EBV infection.
The LMP1 39UTR has previously been reported to be targeted
by multiple EBV BART miRNAs [30], including miR-BART1-5p
which is encoded by B95-8; therefore, we also tested EBV
miRNAs against the LMP1 luciferase reporter (Figure S4E). We
did not, however, observe (i) any cluster mapping to LMP1
bearing a miR-BART1-5p seed match (Tables S10-S14) or (ii) any
inhibition of luciferase activity following ectopic expression of
miR-BART1-5p in 293T cells, indicating that miR-BART1-5p
does not target the LMP1 39UTR (Figures 6D and S4E).
Interestingly, miR-BART3, which does not bear a seed match to
any PAR-CLIP identified cluster, inhibited luciferase activity from
the LMP1 39UTR reporter (Figure S4E). We therefore investi-
gated clusters mapping to the LMP1 39UTR for potential miR-
BART3 binding sites. Indeed, one cluster coincided with a
predicted non-canonical target site, which may explain the
observed luciferase knockdown (data not shown).
In addition to the confirmed miR-17/20/106 site within the
LMP1 39UTR, we identified a second binding site for the miR-
17/20/106 seed family in the 39UTR of BHRF1 (Figure S4;
Tables S10-S14). As the cellular miRNAs for miR-17/92 and
miR-106b/25 clusters are evolutionarily conserved in mammals,
we wondered whether the target sites in the BHRF1 and LMP1
39UTRs might also be conserved. Therefore, we analyzed BHRF1
and LMP1 sequences from the related rhesus lymphocryptovirus
(rLCV; NM_006146) using RNAhybrid and the corresponding
miRNA sequences from Macaca mulatta obtained from miRBASE
v16.0 [63,67]. Intriguingly, predicted mml-miR-17/20/106 bind-
ing sites in both the rLCV BHRF1 and LMP1 39UTRs were
identified, and similar to the hsa-miR-17/20/106 sites in EBV,
exhibited extensive pairing in the seed region (Figure S4A-D).
These observations provide evidence in support of an evolution-
arily conserved role for miR-17/20/106-dependent regulation of
LMP1 and BHRF1 transcripts during viral infection.
Discussion
In this study, we present the EBV and cellular miRNA
targetome in LCLs, which includes ,500 EBV miRNA target
sites in 39UTRs. Using luciferase assays, we experimentally
validated 24 miRNA:39UTR interactions, and 14 target genes of
EBV miRNAs. Furthermore, using BHRF1 miRNA mutant
viruses, we identified a high confidence set of targets that are
specific to EBV-infected LCLs for miR-BHRF1-1 and miR-
BHRF1-3. This study represents the largest set of EBV miRNA
targets to date, and demonstrates that EBV miRNAs predomi-
nantly target cellular genes during latent infection. Presumably,
viral miRNAs reprogram the host environment to favor viral
persistence. Pathway analysis predicts that many of the genes
targeted by EBV miRNAs have roles in p53 feedback loops, B cell
activation, , and apoptosis.
We validated several EBV miRNA targets with potential
immunomodulatory roles. SP100 and ZNF451 are both compo-
nents of promyelocytic leukemia (PML) bodies, which are
implicated in interferon-induced antiviral defenses [68,69].
PDE7A is involved in cytokine production and T cell activation
[70]. miR-BART3-3p and miR-BART1-3p both target the
39UTR of CLEC2D (LLT1), a C-type lectin receptor (CLR) and
NK ligand [64]. We also confirmed the CLR LY75 (DEC205) as a
target of miR-BART1-5p (Figure 3). Additional CLRs including
CLEC2B (AICL), an NKp80 ligand and CLEC7A (Dectin-1) [71]
were also identified as potential EBV miRNA targets (Tables S6,
S10-S14). Interestingly, the CLEC2D, CLEC7A, and LY75
39UTRs all contain predicted seed match binding sites for other
herpesvirus miRNAs, including those expressed by KSHV and
HCMV (data not shown). Furthermore, the NK ligand MICB has
previously been reported to be regulated by multiple herpesvirus
miRNAs, including EBV miR-BART2-5p [28]. We did not detect
a binding site for miR-BART2-5p in the MICB 39UTR by PAR-
CLIP (Tables S10-S14); however, we did identify clusters in the
17/20/106 using a sponge. LCL35 was transduced with pLCE-CXCR4s (control sponge, CXCR4s) or pLCE-miR-17/20/106s (sponge for miR-17/20/106)
and FAC-sorted for high GFP expression. To assay miR-17/20/106 activity, cells were transduced with a firefly luciferase indicator to miR-17-5p and
renilla luciferase as an internal control. For luciferase assays in D and E, lysates were harvested 48-72 hrs post-transfection or post-transduction and
assayed for luciferase activity using the dual luciferase assay kit (Promega). All values are reported as the average of at least two experiments
performed in triplicate with standard deviations and are relative to renilla luciferase (RLU = relative light units). F. Inhibition of endogenous miR-17/
20/106 in LCL35 increases the protein levels of LMP1 and p21 (CDKN1A), a known target of miR-17/20/106. LCL35 was transduced with pLCE-CXCR4s
or pLCE-miR-17/20/106s, FAC-sorted for high GFP expression, and lysates harvested 10 days post-FACS for Western blot analysis. Lanes were loaded
in duplicate. Beta-actin is shown as a loading control.
doi:10.1371/journal.ppat.1002484.g006
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suggesting that MICB may be regulated at some level by EBV
miRNAs. Together, these observations suggest that the downreg-
ulation of multiple CLRs and NK ligands, to prevent recognition
of virally-infected by the host immune system, is a conserved
function of herpesvirus miRNAs.
EBV, KSHV, and HCMV miRNAs do not share seed sequence
homology and therefore, are not predicted to occupy the same
sites on target mRNAs; however, it is conceivable that herpesvi-
ruses have evolved to target different RISC-accessible sites on the
same mRNAs—specifically those target mRNAs that are of
general importance to herpesvirus biology. In fact, of the genes
with seed match sites assigned to EBV miRNAs (Tables S6, S7), a
significant proportion contain predicted seed match sites for either
KSHV or HCMV miRNAs (data not shown). Furthermore,
.50% of the 39UTR sites specifically assigned to cellular miR-
155, which is induced by EBV infection and critical for LCL
growth [20], overlapped with sites present in KSHV+ PEL PAR-
CLIP libraries (Table S6). KSHV expresses the viral miRNA miR-
K11, which has perfect seed homology to miR-155 [21,22], and
thus, these overlapping sites also represent putative targets of
KSHV miR-K11.
At least 14 EBV miRNAs, including those not encoded by B95-
8, share seed sequence homology with cellular miRNAs [46].
Furthermore, this seed sharing for EBV miRNAs is statistically
favored and two times more abundant than what is expected to
occur by chance [25,46]. Theoretically, viral miRNA mimicking
of cellular miRNA seed sequences allows the miRNA to gain
access to and exploit existing host regulatory pathways, thereby
potentially skewing the outcome of miRNA regulation by
occupying those binding sites. Arguably, miR-BART1-3p, and
to some extent miR-BART3-3p as described above (Figure 3D),
regulate the same cellular processes as the miR-29 family
members, which are moderately to highly expressed in LCLs
(Figure 1).
Interestingly, miR-29 is described as both a tumor suppressor
and oncogene [72]. In non-B cells, miR-29 is reported to modulate
Wnt signaling [73]. In B cells, miR-29b downregulates TCL1, an
oncogene that is responsible for the development of aggressive
chronic lymphocytic leukemia (CLL) [72,74]. In EBV-infected B
cells, EBV LMP1 induces the expression of miR-29b, thereby
indirectly downregulating TCL1 protein levels [75]. miR-29 also
targets the MCL1 39UTR, confirmed here (Tables S10-S14),
thereby increasing cell sensitivity to apoptosis [76]. However, over-
expression of miR-29 in transgenic mice can also promote B cell
proliferation [74]. Thus, disrupting finely-tuned miR-29-regulated
processes by EBV miRNAs that mimic the seed sequence of a host
miRNA could have significant consequences.
We observed that EBV miRNAs not only exhibit seed
homology to cellular miRNAs but also share seed homology
amongst themselves (Figures 3D and 4C). This observation arose
while interrogating high confidence targets for miR-BHRF1-1;
several cellular 39UTR clusters can be assigned to both miR-
BHRF1-1 and miR-BART4 due to off-set seed homology between
these two miRNAs. As not all EBV miRNAs are expressed
throughout all stages of latency or in all cell types infected by EBV
[3,5-7], this may be one way EBV can ensure that important
cellular transcripts are nevertheless downregulated.
Three lines of evidence demonstrate that the LMP1 39UTR is
targeted by the c-myc-regulated miRNA clusters miR-17/92 and
miR-106b/25. First, we identified binding sites for the miR-17/
20/106 seed family within the LMP1 39UTR by PAR-CLIP
(Figure 6). Second, luciferase reporter assays confirmed the
interaction, and finally, inhibition of endogenous miRNA
expression using a miRNA sponge lead to an increase in LMP1
protein levels (Figure 6). The presence of a cellular miRNA
binding site in a viral transcript is counterintuitive, especially since
a virus could readily evolve to avoid miRNA targeting. We
observed knockdown of a luciferase reporter following ectopic
miRNA expression and enhanced expression of LMP1 when miR-
17/20/106 miRNAs were inhibited, consistent with the canonical
activity of miRNAs [10]. Thus, this target interaction site does not
appear to provide any novel function, as has been demonstrated
for miR-122 and its interaction with the 59 UTR of hepatitis C
virus (HCV) [77]. We identified a second miR-17/20/106 seed
match site in the BHRF1 39UTR. Furthermore, these miR-17/
20/106 seed match sites appear to be highly conserved in the
rLCV LMP1 and BHRF1 39UTRs (Figure S4). EBV and rLCV
diverged over 13 million years [3], signifying the importance of
these miRNA-interaction sites. The functional relevance of the
miR-17/20/106 site within the LMP1 39UTR is currently
unclear. Preliminary studies with viruses in which the miR-17/
20/106 binding site is mutated indicate that this site is not essential
for B cell transformation in vitro (Feederle et. al., unpublished
observations). Possibly, the downregulation of LMP1, and also
BHRF1, expression by miR-17/20/106 is important during the
transition from latency III to latency I in vivo. Interestingly, both
miR-17/92 and miR-106b/25 are transcriptional targets of c-myc
[65,66]. In latency III LCLs, LMP1-induced NFkB activity is the
major force driving cell survival and proliferation. However, in
EBV+ BL cells, where LMP1 is no longer expressed, c-myc is the
main driver for cellular proliferation [78–80]. Thus, binding of c-
myc-regulated miRNAs to the LMP1 39UTR may be one way to
transition between these seemingly incompatible growth pro-
grams.
In conclusion, our data provides an extensive list of viral and
cellular miRNA targets in B cells. Presumably, many of these
miRNA:mRNA interactions will be of importance to viral
pathogenesis and lymphomagenesis in vivo and for the mainte-
nance of viral latency and/or cell survival in culture. The
identification of a large set of targets for virally encoded or
EBV-induced cellular miRNAs, combined with emerging data
demonstrating the deleterious phenotypic effects that arise upon
loss of these miRNAs in culture [32–34], now sets the scene for
efforts to rescue these phenotypes. For example, short interfering
RNAs (siRNAs) can be used to inhibit the expression of identified,
target mRNAs, thereby elucidating the importance of specific
miRNA targets in the establishment and/or maintenance of EBV
latency.
Materials and Methods
Cell culture and infections
Established lymphoblastoid cell lines (LCLs) are infected with
EBV B95-8 or an EBV B95-8 Bacmid [32,33] (EF3D, EF3D-
AGO2, LCL35, SDLCL, LCL-BAC, LCL-BAC-D1, LCL-BAC-
D3) and were maintained in RPMI 1640 medium supplemented
with 15% FBS and 10 mg/mL gentamicin (GIBCO). LCLs were
analyzed three to five months post-infection. SDLCL has been
previously described [20]. EF3D-AGO2 cells stably express a
FLAG-tagged Ago2 and were generated by transducing EF3D
with pMIGw-FLAG/HA-Ago2-GFP (described below) followed
by sorting for GFP expression. LCL-BAC-D1 (mutationally
inactivated for miR-BHRF1-1 expression) and LCL-BAC-D3
(mutationally inactivated for miR-BHRF1-3 expression) are
infected with EBV miRNA-mutant viruses described in detail
elsewhere [32], and were generated from the same donor as LCL-
BAC.
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with pLCE-sCXCR4 (control sponge, described in [81]) or pLCE-
s17/20/106, containing nine imperfect target sites for miR-17,
miR-20a, or miR-106a in the 39UTR of GFP [81], and FAC-
sorting for high GFP-expressing cells 48-hrs post-infection. FAC-
sorting was done at the Duke Cancer Institute Flow Core Facility.
Virus for all transductions was produced in 293T cells as described
previously [20,22].
Small RNA deep sequencing and preparation of PAR-CLIP
libraries
Small RNA deep sequencing libraries were generated as
previously described [44]. Briefly, 30 mg of total RNA was size-
fractionated on 15% TBE-Urea polyacrylamide gels. Small RNAs
corresponding to 18–24 nt in length were sequentially ligated to 39
and 59 Illumina adapters which are selective for RNAs that have a
59 monophosphate such as miRNAs. Ligated RNAs were reverse
transcribed using SSII (Invitrogen) and cDNAs were PCR
amplified (16–22 cycles) prior to sequencing.
PAR-CLIP libraries were generated as described in [50]. PAR-
CLIP libraries from EBV-negative primary effusion lymphoma
(PEL) cell lines (BCBL1 and BC3) are described in [55]. Briefly,
,1610ˆ9 cells were cultured in the presence of 100 uM 4-
thiouridine (4SU) (Sigma) for 16–18 hrs and then, irradiated at
UV 365 nm. Cells were lysed on ice in NP40-lysis buffer and
cross-linked Ago2:RNA complexes were immunoprecipitated
using either mono-clonal anti-FLAG antibodies (clone M2, Sigma)
for EF3D-AGO2 or monoclonal antibodies to endogenous Ago2
(clone 9E8.2, Millipore). Ago2-bound RNAs were digested with
RNAse T1, radiolabeled, gel-purified, and sequentially ligated to
39 and 59 Illumina adapters for deep sequencing. Ligated RNAs
were reverse transcribed using SSIII (Invitrogen) and cDNAs were
PCR amplified (22-28 cycles). A pilot PCR was performed for each
small RNA or PAR-CLIP library to ensure amplification occurred
in the linear range. Sequencing was performed at the Duke
University IGSP Sequencing Core Facility using an Illumina
GAIIx Sequence Analyzer. Sequencing data was submitted to the
NCBI Sequence Read Archive (SRA) (GEO Accession # in
progress). Processed files can be also accessed online (http://
cullenlab.duhs.duke.edu/publications/sup/).
Bioinformatics
Sequencing reads were pre-processed using the FAST-X toolkit
(http://hannonlab.cshl.edu/fastx_toolkit/) to remove 59 barcode
and 39 adapter sequences. Reads $13 nt in length were aligned
concurrently to the human genome (hg19) and EBV B95-8
genome (NCBI Accession No. V01555.2) or EBV-B95-8 Bacmid
sequence using Bowtie [82]. Up to three mismatches were allowed,
and genomic locations with reads falling into the best stratum (i.e.
lowest number of mismatches) were kept for further analysis. The
number of reads aligned to the human and EBV genomes for
PAR-CLIP libraries is reported in Table S1. For miRNA
annotation, a maximum of 25 different alignment locations was
allowed in order to preserve reads mapping to miRNA families,
and a minimum of five reads aligning to a pre-miRNA location
described in miRBASE v16.0 [67] was required, given that at least
one read aligned with no mismatches.
Further analysis of PAR-CLIP reads was performed using the
PARalyzer pipeline described in detail elsewhere [49]. Briefly,
reads that aligned to a unique genomic location, after subtraction
of T.C mismatches, and overlapped by at least one nucleotide
were grouped together. Read groups were analyzed for T.C
conversions and nucleotide strings containing a greater likelihood
of converted T.Cs than non-converted Ts were extracted as
clusters. Clusters require a read depth of at least five reads, exclude
genomic repeat regions, include sequence from all reads meeting
the T.C conversion criteria, and represent the Ago2:RNA
interaction site. Clusters were interrogated for miRNA 59
canonical seed match sites ($7mer1A, i.e. nt 2-7 match with an
A across from position one of the mature miRNA [10], unless
otherwise noted) using miRNA sequences identified in a matched
small RNA sequencing library. Seed matches described as 12mer
matches also include those matches greater than 12mers. miRNA-
interaction sites (Figure 2B-D, Tables S6 and S7) are subsequently
defined as genomic regions, 8 nt or longer, present in clusters
overlapping in two or more libraries.
Plasmids, miRNA expression vectors, and luciferase
assays
pMIGw-FLAG/HA-Ago2-GFP was generated by PCR-ampli-
fying FLAG/HA-Ago2 from pIRESneo-FLAG/HA-Ago2 [83]
and cloning into pMIGw using BglII and XhoI sites [84]. To
generate miRNA expression vectors, ,300 nt region encompass-
ing each pre-miRNA was PCR amplified from LCL genomic
DNA and cloned into pcDNA3 downstream of the CMV
promoter or into pLCE [81,85] in the GFP 39UTR using XhoI
and XbaI sites. For miR-17/92 and miR-106b/25, regions
encompassing the entire pre-miRNA clusters were cloned. To
assay miRNA expression, indicator vectors were generated
containing a firefly luciferase cassette (pcDNA3-GL3 or pL-
CMV-GL3) and two fully complementary binding sites for the
miRNA of interest inserted using XhoI and XbaI sites into the
39UTR (Table S15). pL-CMV-GL3 and pL-CMV-Rluc, express-
ing renilla luciferase, are derivatives of pLSG and pLSR [81].
pcDNA3-GL3 and pcDNA3-Rluc are derivatives of pL-CMV-
GL3 and pL-CMV-Rluc. To confirm miRNA expression, each
miRNA expression vector was tested against its respective
indicator (data not shown) as well as empty vector (control in
Figure S3).
Target 39UTRs identified by PAR-CLIP were PCR amplified
from LCL genomic DNA using primers in Table S15 and inserted
into the 39UTR of firefly luciferase in pLSG or pcDNA3-GL3
(XhoI, XbaI). Luciferase reporters containing the 39UTR of
BACH1 or CDKN1A are previously described [22,81]. 293T
cells were transfected in 24-well plates with 10 ng firefly luciferase
reporter (pLSG with indicated 39UTR), 5 ng pLSR or pCMV-
RLuc expressing renilla luciferase, and 1 mg miRNA expression
plasmid using Fugene 6 according to the manufacturer’s protocol
(Roche). 48–72 hrs post-transfection, cells were lysed in 1X passive
lysis buffer (Promega) and luciferase expression was assayed using
the dual reporter luciferase assay system (Promega). All luciferase
assays are reported as the average of two to five independent
experiments performed in triplicates, and p-values were deter-
mined by Student’s t test.
Primer extension assays
Primer extensions were performed with 10 mg of total RNA
using the AMV PE kit according to the manufacturer’s protocol
(Promega). Oligonucleotides used for probes are listed (Table S15)
and were end-labeled using c32P-ATP and T4 polynucleotide
kinase. Reverse transcription products were separated on 15%
TBE-urea polyacrylamide gels and exposed to film.
Western Blot analysis
Cells were lysed in lysis buffer containing 1% NP40, 50 mM
Tris, and 150 mM NaCl. Protein concentrations were determined
using the BCA protein assay kit (Thermo Scientific) and 10 mg
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Following electrophoresis, proteins were transferred to nitrocellu-
lose and membranes were probed with primary antibodies to
LMP1 (monoclonal, clone S12), p21 (c-19, Santa Cruz), or beta-
actin (c4, Santa Cruz). Corresponding horse-radish peroxidase
(HRP) conjugated secondary antibodies were to mouse (LMP1 and
beta-actin) or rabbit (p21). Blots were developed using LumiLight
western blot substrate (Roche), for LMP1 or beta-actin, or
SuperSignal West Femto maximum sensitivity substrate for p21
(Thermo Scientific) and exposed to film.
Pathway analysis
Pathway analysis was performed using PANTHER (www.
pantherdb.org). 39UTRs and CDSs assigned to EBV miRNAs that
occurred in at least two of the five PAR-CLIP libraries were input
using all CLIPed genes (11,057 mapped genes) as the reference list.
The human genome (19,911 genes) was interrogated as a second
reference list. Biological processes were sorted according to p-
value. Reported are the top 20 pathways targeted by EBV
miRNAs.
Supporting Information
Figure S1 Analysis of PAR-CLIP clusters. A. Overlap
between the five PAR-CLIP libraries. Shown is the percent of
clusters (including 39UTRs, 59UTRs, CDS, and intergenic sites)
within individual libraries that can be identified in at least one
other PAR-CLIP library. Clusters from separate libraries were
considered overlapping if they shared at least 50% of their
nucleotides (also for C and D). B. Clusters are preferentially
distributed towards the termini of 39UTRs. Plotted is the number
of PAR-CLIP identified clusters against their relative position in a
39UTR for LCL35. Similar results were observed for the other
libraries (not shown). C. Clusters with high read counts are more
consistently captured in multiple libraries than clusters with low
read counts. The average PAR-CLIP read value of clusters for any
particular set of overlapping clusters was recorded. This value was
then plotted by the number of libraries that had a cluster within
the set of overlapping clusters. D. Clusters with seed matches to
highly expressed miRNAs are more consistently captured in
multiple libraries than clusters with seed matches to weakly
expressed miRNAs. The miRNA with the highest expression value
assigned to any one of the clusters within the set of overlapping
clusters was recorded. This value was then plotted by the number
of libraries that had a cluster within the set of overlapping clusters.
(EPS)
Figure S2 PAR-CLIP identifies previously reported
miRNA targets. A-C. Overlap of the 2,337 mRNAs enriched
in Ago2-immunoprecipitations from human B cells (Do ¨lken, et. al.,
2010) with high-confidence PAR-CLIP-identified miRNA-inter-
action sites that were present in at least two of the five libraries
(39UTRs and/or CDSs from Tables S6 and S7). Venn diagrams
were generated using the online tool from the MIT Whitehead
Institute: http://jura.wi.mit.edu/bioc/tools/D. Overlap of previ-
ously reported miR-155 targets with high-confidence PAR-CLIP-
identified miRNA-interaction sites that were present in at least two
of the five libraries (39UTRs only from Table S6). Also see Table
S8.
(EPS)
Figure S3 Cellular targets of EBV and cellular miRNAs
confirmed by luciferase reporter assays. 39UTRs for
indicated genes were inserted into the 39UTR of firefly luciferase.
39UTR reporter plasmids were co-transfected into 293T cells with
indicated miRNA expression plasmids; lysates were harvested 72
hrs post-transfection and assayed for luciferase activity. All values
are shown relative to an internal renilla luciferase control. Reported
are the averages of two to five independent experiments performed
in triplicates. (RLU = relative light units) miRNA:39UTR
combinations that were identified by PAR-CLIP and show
knockdown by luciferase reporter assays are highlighted in dark
red; those miRNA:39UTR combinations that did not respond as
predicted by PAR-CLIP are highlighted in pink. Highlighted in
grey are 39UTRs which respond to ectopic miRNA expression but
were not identified as targets by PAR-CLIP. *indicates statistically
significant knockdown (p,0.05), but does not meet the .20%
knockdown cut-off. **39UTR contains a canonical seed match
(minimally nt 2-7) or seed match with G:U pairing (minimally nt 2-
8) to the respective miRNA. Two of these predicted miR-
NA:39UTR interaction sites with G:U pairing in the seed coincide
with PAR-CLIP clusters that could not be assigned to any miRNAs.
(EPS)
Figure S4 The miR-17/20/106 binding sites in LMP1
and BHRF1 are conserved in rLCV. A-D. The EBV and
rLCV latent transcripts, LMP1 and BHRF1, contain miR-17/20/
106 seed match sites in their 39UTRs. Sequences of the LMP1 (A
and B) and BHRF1 (C and D) 39UTRs from EBV and rLCV were
analyzed for miR-17/20/106 seed match sites using RNAhybrid.
Shown are the PAR-CLIP identified sites for human miR-17/20/
106 in EBV mRNAs and the predicted sites for macaque miR-17/
20/106 in rLCV mRNAs. E. The LMP1 39UTR luciferase
reporter responds to EBV miR-BART3. The LMP1 39UTR
reporter was co-transfected into 293T cells with indicated EBV
miRNA expression plasmids; lysates were harvested 72 hrs post-
transfection and assayed for luciferase activity. All values are
shown relative to an internal renilla luciferase control. Reported
are the averages of at least two independent experiments
performed in triplicates. (RLU = relative light units)
(EPS)
Table S1 Deep sequencing reads aligned to the human
and EBV genomes.
(XLS)
Table S2 miRNAs detected in EF3D-AGO2.
(CSV)
Table S3 miRNAs detected in LCL35.
(CSV)
Table S4 miRNAs detected in LCL-BAC.
(CSV)
Table S5 miRNAs detected in SDLCL.
(CSV)
Table S6 High confidence miRNA-interaction sites in
39UTRs.
(XLS)
Table S7 High confidence miRNA-interaction sites in
CDSs.
(XLS)
Table S8 Previously reported miR-155 targets detected
in PAR-CLIP.
(XLS)
Table S9 Previously reported EBV miRNA targets.
(XLS)
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Table S11 miRNA seed matches in LCL35 clusters.
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Table S12 miRNA seed matches in LCL-BAC clusters.
(CSV)
Table S13 miRNA seed matches in LCL-BAC-D1 clus-
ters.
(CSV)
Table S14 miRNA seed matches in LCL-BAC-D3 clus-
ters.
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Table S15 Oligonucleotide sequences.
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